日韩成人无码毛片,成人无码A级毛片免费播放,精品乱码一区内射人妻无码,强伦轩人妻一区二区三区四区,欧美一级婬片AAAAAAA欠钱,亚洲精品乱码久久久久久蜜桃91,中文在线字幕免费观看,免费看无码一级A片放24小时 ,精品人妻少妇嫩草AV无码专区,99人妻碰碰碰久久久久禁片,国内精品一区二区,老熟妇欲乱AV无码 ,国产69精品久久久久久久久久久久,www.17c路com,国产成人在线视频,91久久精品国自产合

最近搜索:細(xì)胞培養(yǎng) 微生物學(xué) 分子生物 生物化學(xué)
首頁>>免疫學(xué)>>一抗>>骨保護(hù)蛋白/護(hù)骨素抗體
骨保護(hù)蛋白/護(hù)骨素抗體
  • 產(chǎn)品貨號:
    BN40613R
  • 中文名稱:
    骨保護(hù)蛋白/護(hù)骨素抗體
  • 英文名稱:
    Rabbit anti-OPG Polyclonal antibody
  • 品牌:
    Biorigin
  • 貨號

    產(chǎn)品規(guī)格

    售價

    備注

  • BN40613R-100ul

    100ul

    ¥2360.00

    交叉反應(yīng):Human,Mouse,Rat(predicted:Dog,Rabbit) 推薦應(yīng)用:WB,IHC-P,IHC-F,ICC,IF,ELISA

  • BN40613R-200ul

    200ul

    ¥3490.00

    交叉反應(yīng):Human,Mouse,Rat(predicted:Dog,Rabbit) 推薦應(yīng)用:WB,IHC-P,IHC-F,ICC,IF,ELISA

產(chǎn)品描述

英文名稱OPG
中文名稱骨保護(hù)蛋白/護(hù)骨素抗體
別    名MGC29565; OCIF; OPG; Osteoclastogenesis Inhibitory Factor; TNFRSF 11B; TNFRSF11B; TR 1; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; TR11B_HUMAN.  


研究領(lǐng)域腫瘤  細(xì)胞生物  免疫學(xué)  信號轉(zhuǎn)導(dǎo)  骨髓細(xì)胞  
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng)Human, Mouse, Rat,  (predicted: Dog, Rabbit, )
產(chǎn)品應(yīng)用WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量44kDa
細(xì)胞定位分泌型蛋白 
性    狀Liquid
濃    度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human OPG:201-300/401 
亞    型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMedPubMed
產(chǎn)品介紹Osteoprotegerin (OPG, or osteoclastogenesis inhibitory factor) is a secretory glycoprotein belonging to TNF receptor superfamily. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. OPG acts as a soluble factor in the regulation of bone mass and may be beneficial in the treatment of osteoporosis with increased osteoclast activity. OPG consists of 401 amino acids with a molecular weight of 44 kDa as a monomer and 90 kDa as a disulphide-linked dimer.

Function:
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.

Subunit:
Homodimer.

Subcellular Location:
Secreted.

Tissue Specificity:
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.

Post-translational modifications:
N-glycosylated. Contains sialic acid residues.
The N-terminus is blocked.

DISEASE:
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.

Similarity:
Contains 2 death domains.
Contains 4 TNFR-Cys repeats.

SWISS:
O00300

Gene ID:
4982

Database links:

Entrez Gene: 4982 Human

Omim: 602643 Human

SwissProt: O00300 Human

Unigene: 81791 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

護(hù)骨素又稱護(hù)骨因子(osteorotegenin,OPG)、骨保護(hù)蛋白、破骨細(xì)胞生成抑制因子、骨保護(hù)素、破骨細(xì)胞抑制生成因子(osteoclastogenesis inhibitory factor,OCIF)
OPG屬于TNF受體超家族,主要功能是抑制破骨細(xì)胞的分化、成熟破骨細(xì)胞的骨吸收活性,并誘導(dǎo)其凋亡。
























image.png

image.png

image.png

image.png

image.png

image.png


苏州市| 六安市| 孙吴县| 奉节县| 河津市| 贵溪市| 黔东| 库尔勒市| 赤壁市| 沁源县| 崇义县| 钦州市| 延长县| 四平市| 常州市| 桦川县| 伽师县| 正安县| 元朗区| 孝昌县| 青阳县| 巴楚县| 林口县| 昔阳县| 边坝县| 毕节市| 柳江县| 太和县| 洛南县| 江北区| 曲靖市| 鄂托克旗| 尚义县| 娄底市| 洮南市| 宁波市| 东乡县| 布尔津县| 静宁县| 周宁县| 聊城市|